图：Royal Society uploader · CC BY-SA 4.0 · Wikimedia Commons

Daniel J. Drucker1956—

Canadian endocrinologist

沃尔夫医学奖 2023

Daniel Joshua Drucker is a Canadian endocrinologist renowned for his breakthrough discoveries of the biological actions of glucagon-like peptides GLP-1 and GLP-2, including GLP-1's key role in stimulating glucose-dependent insulin secretion, reducing food intake, protecting the heart, and reducing systemic inflammation. His scientific research has been a driving force in GLP-1's journey from a newly discovered peptide sequence to the mechanism behind globally used and life-changing therapeutics for type 2 diabetes and obesity. It has also driven transformative new therapeutics for intestinal failure and other metabolic disorders. A Fellow of the Royal Society, and laureate of the 2023 Wolf Prize in Medicine, he is a University Professor of Medicine at the University of Toronto and Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto.

摘自英文维基百科「Daniel J. Drucker」（英文维基百科，暂无中文条目），CC BY-SA 4.0

英文维基百科 Wikidata

出生: 1956 年 6 月 23 日，蒙特利尔
国籍: 加拿大
学科: 生物学
母校: 多伦多大学、多伦多大学医学院（医学士，1980 年）
工作单位: 多伦多大学、西奈山医院

研究领域

肠降血糖素糖尿病

所获奖项（11）

2009Outstanding Clinical Investigator Award
2014Banting Medal
2015加拿大勋章官佐
2015英国皇家学会院士
2020华伦阿尔波特奖
2021盖尔德纳国际奖
2022加拿大医学名人堂
2023沃尔夫医学奖
2024阿斯图里亚斯亲王奖科学技术奖
2025Fred Conrad Koch Award
2025生命科学突破奖

学会与院士

英国皇家学会美国国家科学院

百科正文

本条目暂无中文维基百科条目，下面是英文维基百科原文。

Early life and education

Drucker was born and grew up in Montreal, went to high school in Ottawa, and then enrolled at the University of Ottawa, studying science. In 1976, he moved to Toronto, where he studied medicine at the University of Toronto, graduating in 1980. He completed his internship at Johns Hopkins Hospital (1980–81) and completed his internal medicine and endocrinology residencies at the University of Toronto (1981–84).

Career and research

In 1984, Drucker began his research career at Massachusetts General Hospital and Harvard Medical School, studying molecular endocrinology in the lab of Professor Joel Habener with the support from a Medical Research Council of Canada Centennial Fellowship. Drucker’s independent discoveries in Boston included the demonstration that proglucagon could be cleaved into multiple glucagon-like peptides, including several distinct isoforms of GLP-1. He then discovered that the truncated form of GLP-1(7-37) directly stimulated cyclic AMP formation, insulin secretion, and insulin gene expression; notably, it did so only when glucose levels were elevated.

Further discoveries of the therapeutic potential of GLP-1 at University of Toronto

In 1987 Drucker returned to Toronto, taking on the position of Assistant Professor of Medicine at the University of Toronto and continuing his research on the glucagon-like peptides while also working as a physician. In 1996, Drucker was one of several investigators who demonstrated that GLP-1 reduced food intake in preclinical studies. Notably, the experiments in the Drucker lab demonstrated that this action of GLP-1 in the brain required the functional canonical GLP-1 receptor. Drucker, together with colleagues at Tufts Universities, filed multiple patents describing the utility of targeting the DPP-4 enzyme, and published studies demonstrating that genetic or chemical inactivation of DPP-4 prevented degradation of GLP-1 and GIP, supporting the development of DPP-4 inhibitors for the treatment of type 2 diabetes. In all, Drucker's discovery science has led to 33 issued US patents supporting translational drug development efforts in the field of peptide based therapeutics. Collectively, the body of work from multiple investigators and companies led to the development of two leading classes of diabetes medications: GLP-1 receptor agonists and DPP4 inhibitors.

Discovery of GLP-2 actions leading to Short Bowel Syndrome treatments

In 1996, Drucker also discovered the first biological actions for GLP-2, demonstrating that it augmented crypt cell proliferation and expansion of the mucosal epithelium in the small bowel of mice and rats. He subsequently identified and characterized a DPP-4-resistant molecule, teduglutide, that was ultimately developed and approved for the treatment of short bowel syndrome in adults and children, a disorder in which fluids are poorly absorbed after resection of the small intestine.

Research supporting the development, safety and benefits of GLP-1 therapeutics

Drucker joined the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto in 2006. In 2008 he led studies aimed at the development and testing of the first long-acting, once-weekly version of the diabetes medication exenatide. He later studied the long-term effects of related weight-loss medicines on bowel health. Drucker has also led the identification of the cardioprotective mechanisms of GLP-1 action.

Awards and honours

2007 Donald F. Steiner Award for Outstanding Diabetes Research, University of Chicago
2008 Prix Galien Canada for Outstanding Pharmaceutical Research
2009 Clinical Investigator Award, Endocrine Society
2012 Claude Bernard Prize, European Association for the Study of Diabetes
2012 Fellow of the Royal Society of Canada
2013 Oon International Award for Preventative Medicine, University of Cambridge
2014 Banting Medal for Scientific Achievement, American Diabetes Association
2014 Manpei Suzuki Foundation International Prize for Diabetes, Japan
2015 Fellow of the Royal Society
2015 Officer of the Order of Canada
2017 Rolf Luft Award in Endocrinology and Diabetes Research, Karolinska Institute

2017 Harrington Prize for Innovation in Medicine, American Society for Clinical Investigation and the Harrington Institute (co-recipient with Joel Habener and Jens Juul Holst)

2019 Harold Hamm International Prize for Biomedical Research in Diabetes

2019 Novo Nordisk Foundation and European Association for the Study of Diabetes Prize for Excellence in Diabetes Research (watch the mini documentary about Drucker produced by the Novo Nordisk Foundation for the occasion)

2019 Lifetime Achievement Award, Helmholtz Diabetes Centre, Germany
2020 John Baxter Award for Entrepreneurship, Endocrine Society
2020 Transatlantic Medal, Society for Endocrinology

2020 Warren Alpert Foundation Prize for Biomedical Research (co-recipient with Joel Habener and Jens Juul Holst)

2021 International Member, National Academy of Sciences

2021 Canada Gairdner International Award (co-recipient with Joel Habener and Jens Juul Holst)

2022 Inductee of the Canadian Medical Hall of Fame
2023 Wolf Prize in Medicine
2023 International Member of the National Academy of Medicine

2023 VinFuture Prize for Innovators with Outstanding Achievements in Emerging Fields (co-recipient with Joel Habener, Jens Juul Holst and Svetlana Mojsov)

2024 Princess of Asturias Award for Technical and Scientific Research (co-recipient with Jeffrey M. Friedman, Joel Habener, Jens Juul Holst and Svetlana Mojsov)